Combination vaccine devices and methods of killing cancer cells
AssigneesPresident and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
InventorsOmar Abdel-Rahman Ali, David J. Mooney, Glenn Dranoff
Life of this patent
Estimating the term…
Abstract
The present invention comprises compositions, methods, and devices for enhancing an endogenous immune response against a cancer. Devices and methods provide therapeutic immunity to subjects against cancer.
Claims21
A method of treating a poorly immunogenic cancer in a subject in need thereof, wherein the poorly immunogenic cancer is resistant to cytotoxic T-lymphocyte (CTL)-mediated lysis or natural killer (NK) cell mediated killing, the method comprising administering to the subject:
- a) an inhibitor of an immune checkpoint protein;
- and
- b) a device comprising
- (i) a macroporous scaffold composition comprising open, interconnected pores,
- (ii) a cell recruitment composition that recruits an immune cell, wherein the cell recruitment composition is selected from the group consisting of a cytokine, a chemokine, a growth factor, and a combination thereof;
- and
- (iii) an antigen derived from the cancer,
- wherein the inhibitor is administered concurrent and subsequent to the administration of the device, wherein the subsequent administration is in the absence of the device, and wherein the method enhances the CD8 T cell:
- Treg cell ratio in the cancer, thereby treating the cancer.
A method of treating a poorly immunogenic cancer a subject in need thereof, wherein the poorly immunogenic cancer is resistant to cytotoxic T-lymphocyte (CTL)-mediated lysis or natural killer (NK) cell mediated killing, the method comprising administering to the subject:
- a) an antibody selected from the group consisting of an anti-PD1 antibody, an anti-CTLA4 antibody, and a combination thereof;
- b) a device comprising
- (i) a PLG macroporous scaffold comprising open, interconnected pores,
- (ii) a granulocyte macrophage-colony stimulating factor (GM-CSF);
- and
- (iii) a tumor cell lysate,
- wherein the antibody is administered concurrent and subsequent to the administration of the device, wherein the subsequent administration is in the absence of the device, and wherein the method enhances the CD8 T cell:
- Treg cell ratio in the cancer, thereby treating the cancer.
Dependencies are inferred from the claim text.